+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in adults aged 55 to 90 who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how these treatments may impact agitation symptoms in this population. The study is sponsored by Bristol-Myers Squibb and focuses on agitation as a complication of Alzheimers disease. Participants will be randomly assigned to receive either the combination of XanomelineTrospium Chloride Capsule and Xanomeline Enteric Capsule or a placebo. The treatments are given at specified doses on designated days. The study uses a parallel group design to compare these two options over a treatment period lasting up to 14 weeks. During the study, participants and their caregivers will attend regular visits for assessments including agitation severity using the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association total score, clinical global impressions, and other neuropsychiatric evaluations. Safety will be closely monitored through adverse event reporting and various clinical tests, including movement scales, vital signs, lab tests, ECGs, and assessments for suicidal thoughts. Caregivers will help oversee medication compliance and report on participant status. The entire study period extends through Week 18 for safety follow-up.

Age: 55Years - 90YearsAll GendersPhase 3
143 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide compared to placebo in people with opioid use disorder OUD who are also receiving buprenorphine treatment, with or without naloxone. This Phase 2 study includes participants with mild to severe OUD and aims to assess abstinence from opioid use over a defined period. The study has two parts Part A involves a double-blind treatment phase followed by an open-label extension, while Part B includes only open-label treatment. Participants receive brenipatide or placebo by subcutaneous injection alongside buprenorphine administered under the tongue or in the cheek. Each participant enrolls in only one part, with treatment durations up to approximately 144 weeks in Part A and 116 weeks in Part B. Participants attend regular study visits for assessments, including urine drug screens and self-reports to measure opioid abstinence, adherence to buprenorphine, and changes in craving and quality of life. Other evaluations include monitoring for overdose events, healthcare utilization, body measurements, and blood pressure. Safety is tracked through laboratory tests and antibody monitoring, with the overall study lasting up to several years depending on enrollment timing.

Age: 18Years - 75YearsAll GendersPhase 2
68 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of trontinemab in people aged 55 to 80 who have biological signs of Alzheimers Disease but no current cognitive or functional problems. The study focuses on individuals at risk of progressing to mild cognitive impairment or dementia due to Alzheimers disease, aiming to understand if trontinemab can delay or prevent this progression. Participants will be randomly assigned to receive either intravenous trontinemab or a placebo. The study is designed as a double-blind, parallel-group trial, meaning neither participants nor researchers know who receives the drug or placebo. Treatment and monitoring will continue for up to approximately six years, with regular assessments throughout this period. During the study, participants will undergo various cognitive tests, brain imaging scans, and blood biomarker measurements to track changes in memory, thinking skills, and brain amyloid levels. Researchers will also monitor safety by recording any adverse events or reactions. The main outcome measured is the time it takes for participants to develop symptoms of dementia, with follow-up continuing for up to six years to gather comprehensive data.

Age: 55Years - 80YearsAll GendersPhase 3
34 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT in treating psychosis associated with Alzheimers Disease AD in people aged 55 to 90 years. This Phase 3 study compares KarXT to a placebo to see how well it helps reduce hallucinations and delusions in patients with mild to severe AD psychosis. The study measures changes using the Neuropsychiatric Inventory-Clinician NPI-C score focused on hallucinations and delusions. Participants receive either KarXT capsules at varying doses or placebo capsules in a randomized, double-blind manner. The treatment period lasts up to 14 weeks, during which researchers monitor symptoms and side effects. KarXT doses range from 202 mg up to 66.76.67 mg daily, assessing safety and efficacy compared to placebo. During the study, participants undergo assessments including clinical scales such as the NPI-C and the Clinical Global Impressions-Severity CGI-S scale. Caregiver distress and other behavioral symptoms are also evaluated. Researchers track changes from baseline to the end of treatment. The study includes safety monitoring and aims to understand KarXTs impact over the 14-week treatment period.

Age: 55Years - 90YearsAll GendersPhase 3
157 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of combining KarXT and KarX-EC as a treatment for psychosis associated with Alzheimers disease. This Phase 3 randomized, double-blind, placebo-controlled trial aims to address psychotic symptoms such as hallucinations and delusions in patients aged 55 to 90 diagnosed with Alzheimers disease according to recent criteria. The study is sponsored by Bristol-Myers Squibb and uses a parallel group design to compare the investigational drug combination against placebo. Participants will be randomly assigned to receive either the combination of KarXT plus KarX-EC or a matching placebo, with specified doses given on set days. The treatment period lasts approximately 14 weeks, during which safety and efficacy are closely monitored. The trial assesses changes from baseline in neuropsychiatric symptoms and other clinical measures using standardized scales and questionnaires. During the study, participants will undergo various assessments including clinical evaluations, laboratory tests, brain imaging review, and symptom rating scales such as the Neuropsychiatric Inventory-Clinician and Clinical Global Impressions-Severity. Researchers will also monitor adverse events and other health indicators up to about week 14. The total participation duration spans from screening through treatment completion and safety follow-up to evaluate the overall impact and safety profile of the treatments.

Age: 55Years - 90YearsAll GendersPhase 3
22 locations
L

Actively Recruiting

Researchers are investigating the long-term safety and effectiveness of a combined drug treatment using xanomeline tartratetrospium chloride in an immediate release capsule KarXT and xanomeline enteric capsules KarX-EC for people with agitation linked to Alzheimers Disease. This study is an open-label extension of earlier studies CN012-0023 and CN012-0024. It aims to understand how well these treatments work over time and monitor any side effects. Participants who completed the previous studies will receive specified doses of KarXT and KarX-EC according to a set schedule. This phase 3 study does not include a comparison group and all participants receive the combined treatment. The treatment period lasts approximately 30 weeks, during which the effects and safety of these medications will be observed. During the study, participants will be closely monitored for any adverse events, changes in cognitive function, movement disorders, vital signs, and other health measures. Assessments include scales like the Mini-Mental State Examination MMSE, Abnormal Involuntary Movement Scale AIMS, and others related to agitation and side effects. Safety checks such as lab tests, ECGs, and questionnaires will be regularly conducted. The total study duration for participants is about 30 weeks, with follow-up to evaluate overall treatment tolerability and impact.

Age: 55Years - 90YearsAll GendersPhase 3
252 locations
S

Actively Recruiting

Researchers are investigating the effects and safety of the medicine PF-07275315 for treating moderate to severe Chronic Obstructive Pulmonary Disease COPD, a lung condition that makes breathing difficult and impacts daily life. This interventional study involves adults aged 35 to 80 who have had COPD for at least 12 months and experienced at least two moderate or severe exacerbations in the past year while on stable maintenance treatment. Participants will receive either PF-07275315 or a placebo through multiple subcutaneous injections at the clinic. The Phase 2 portion lasts 24 weeks with study involvement totaling about 40 weeks and includes 11 clinic visits. The Phase 3 portion lasts 52 weeks with approximately 68 weeks total involvement and 18 clinic visits. The study compares outcomes between those receiving PF-07275315 and those receiving placebo to evaluate safety and effectiveness. During the study, participants will undergo regular assessments including lung function tests such as forced expiratory volume FEV1, monitoring of exacerbation rates, symptom questionnaires, safety lab tests, electrocardiograms, and vital signs. Safety and adverse events will be closely tracked throughout the study, and participants will be followed for the full duration of their assigned phase to monitor changes and outcomes related to COPD.

Age: 35Years - 80YearsAll GendersPhase 2Phase 3
189 locations
T

Actively Recruiting

Researchers are evaluating treatments for symptomatic Alzheimers Disease in a Phase 3 trial designed to measure sustained clinical response over 18 months. The study uses a multi-arm, multi-stage adaptive design to compare standard care plus placebo, atomoxetine, or metformin in participants representative of the UK Alzheimers population. The trial aims to assess changes in cognitive function and daily living activities, with additional focus on symptoms, quality of life, caregiver impact, safety, and economic outcomes. Participants are randomly assigned to one of three groups receiving standard care plus either a placebo capsule, oral atomoxetine up to 100 mg daily, or oral metformin up to 2000 mg daily. The trial includes interim analyses at several stages to decide if any treatment arm should be stopped early due to lack of activity. Blood biomarkers and MRI scans are also collected to explore disease progression and treatment effects. During the study, participants will undergo assessments including cognitive tests, daily living activity questionnaires, neuropsychiatric evaluations, quality of life surveys, and caregiver burden measures at baseline and throughout 18 months. Safety is monitored by tracking adverse events and health resource use. MRI imaging and blood samples are used for exploratory analyses. Participants are expected to adhere to treatment and assessment schedules, with regular visits for evaluation and monitoring throughout the trial period.

Age: 55Years +All GendersPhase 3
2 locations
U

Actively Recruiting

Researchers are conducting a multi-centre observational study to better understand giant cell arteritis GCA and polymyalgia rheumatica PMR, conditions mainly affecting people over 50 years old. The study aims to identify genetic factors that influence susceptibility to these diseases to provide new insights into how they develop. It includes both retrospective participants with confirmed diagnoses and prospective participants suspected of having these conditions, with some patients also enrolled in a registry monitoring tocilizumab treatment for relapsing or refractory GCA. The study collects detailed clinical, imaging, and molecular data, including genetic and proteomic analyses, from participants to characterize disease subtypes and impacts. Researchers also assess quality of life through patient-reported outcomes and track long-term prognosis by linking to health records. The study explores environmental factors and co-existing conditions to improve diagnosis, prognosis, and monitoring of disease activity, especially for patients receiving synthetic or biological disease-modifying anti-rheumatic drugs. Participants provide information during baseline assessments, including blood and urine samples for analysis, and complete questionnaires about their symptoms and quality of life. Follow-up occurs through health record review over an average of one year to evaluate diagnosis and disease outcomes. The primary measure is genetic susceptibility, with secondary outcomes focusing on disease characteristics, life impact, diagnosis, and disease activity. The study is sponsored by the University of Leeds and started in 2005, continuing through 2028.

Age: 50Years +All Genders
76 locations
P

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of subcutaneous treatment with lunsekimig compared with placebo in adults aged 40 to 80 years who have inadequately controlled Chronic Obstructive Pulmonary Disease COPD characterized by an eosinophilic phenotype. This Phase 2bPhase 3 study includes participants with a history of COPD, ongoing symptoms despite treatment, and specific lung function and blood eosinophil criteria. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a placebo group. All treatments are given as subcutaneous injections during a 48-week treatment period. The study consists of a screening period up to 4 weeks, followed by the 48-week randomized treatment, and then an approximately 8-week follow-up period, totaling up to 60 weeks of participation. During the study, participants will undergo lung function tests, symptom and quality of life questionnaires, and blood tests to monitor eosinophil counts and drug levels. The main outcome measured is the annualized rate of moderate-to-severe COPD exacerbations over 48 weeks. Additional assessments include changes in lung function, symptom scores, safety events, and antibody development. Safety monitoring continues through the follow-up period after treatment ends.

Age: 40Years - 80YearsAll GendersPhase 3
314 locations

1-10 of 18

1